Wecome Pharmaceutical Co Ltd Capital Reinvestment Ratio
Wecome Pharmaceutical Co Ltd capital reinvestment ratio. Wecome Pharmaceutical Co Ltd (300878) has a Capital Reinvestment Ratio of 0.01x as of June 2025, meaning it reinvests 0% of its operating cash flow (CN¥50.89 Million) in capital expenditures (CN¥389.97K). Check 300878 capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Wecome Pharmaceutical Co Ltd (2013–2023)
Capital reinvestment ratio of Wecome Pharmaceutical Co Ltd from 2013 to 2023. This chart tracks Wecome Pharmaceutical Co Ltd's Capital Reinvestment Ratio across 10 annual periods. Also explore net asset growth rate of Wecome Pharmaceutical Co Ltd to track the company's year-over-year net asset growth rate.
Wecome Pharmaceutical Co Ltd Capital Reinvestment Ratio by Year (2013–2023)
Wecome Pharmaceutical Co Ltd capital reinvestment ratio by year from 2013 to 2023. For the full cash flow conversion analysis, see 300878 cash generation efficiency.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2023 | 2.39x | CN¥58.29 Million | CN¥139.29 Million | ▲ +41.0% |
| 2022 | 1.70x | CN¥146.57 Million | CN¥248.44 Million | ▼ -52.4% |
| 2020 | 3.56x | CN¥42.81 Million | CN¥152.34 Million | ▲ +249.0% |
| 2019 | 1.02x | CN¥112.76 Million | CN¥114.98 Million | ▼ -37.7% |
| 2018 | 1.64x | CN¥105.57 Million | CN¥172.73 Million | ▲ +12.9% |
| 2017 | 1.45x | CN¥29.00 Million | CN¥42.04 Million | ▲ +202.7% |
| 2016 | 0.48x | CN¥100.15 Million | CN¥47.97 Million | ▼ -63.1% |
| 2015 | 1.30x | CN¥29.63 Million | CN¥38.48 Million | ▲ +46.9% |
| 2014 | 0.88x | CN¥46.01 Million | CN¥40.68 Million | ▲ +100.2% |
| 2013 | 0.44x | CN¥25.98 Million | CN¥11.48 Million | — |